This product is an ASHP Learning Center https://elearning.ashp.org/ activity.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Target Audience
The Specialty Pharmacy: Oncology and Hematology Disease States Certificate is self-guided, with online learning activities that have been created for pharmacists seeking to expand their skills in specialty pharmacy management of oncology and hematology disease states.
Overview
The Specialty Pharmacy Certificate is self-guided, with online learning activities that have been created for pharmacists seeking to expand their skills in specialty pharmacy.
A learner will have completed the Specialty Pharmacy Fundamentals before beginning the Oncology and Hematology Disease States Track.
The learner will then take a deep dive into their selected specialty focus with the Oncology and Hematology Disease States Track. These topics include oncology supportive care, breast cancer, dem-oncology, neuro-oncology, colorectal cancer, hematology (AML, ALL, CML, CLL, multiple myeloma), stem cell transplant, hepatic and renal cancer, prostate cancer, and non-small cell lung cancer.
Specialty Pharmacy: Oncology and Hematology Disease States Professional Certificate Requirement
Once a learner has completed the Specialty Pharmacy Fundamentals and the Oncology and Hematology Disease States Track educational curriculum, they will have the opportunity to complete the track’s final exam. Once the learner successfully completes the track’s final exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the Specialty Pharmacy: Oncology and Hematology Disease States Professional Certificate.
Educational Activities
Specialty Pharmacy: Oncology and Hematology Disease States Track
Introduction to Oncology Care
ACPE: 0204-0000-25-885-H01-P
Application-based
1.75 contact hours
Learning Objectives:
- Differentiate hematology/oncology organizations and their roles in practice.
- Define basic hematology/oncology concepts, including terminology, tumor staging, and dosing.
- Apply guideline recommendations in choosing an antiemetic regimen for cancer patients.
- Select agents for management of acute and chronic graft-versus-host disease (GVHD).
- Analyze patient characteristics for appropriate use of granulocyte colony stimulating factor (GCSF).
Breast Cancer
ACPE: 0204-0000-25-886-H01-P
Application-based
2.75 contact hours
Learning Objectives:
- Summarize breast cancer risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
- Develop a patient-specific pharmacotherapy plan for early-stage breast cancer.
- Explain recurrent and metastatic breast cancer characteristics and pathology.
- Compare therapies used in HR+ recurrent and metastatic breast cancer.
- Compare targeted medication therapies for recurrent and metastatic breast cancer.
- Develop a patient-specific medication therapy treatment plan for a patient with breast cancer.
Derm-oncology, Neuro-oncology, and Colorectal Cancer
ACPE: 0204-0000-25-887-H01-P
Application-based
2.75 contact hours
Learning Objectives:
- Summarize cutaneous oncology risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
- Develop a patient-specific pharmacotherapy plan for basal cell carcinoma.
- Develop a patient-specific pharmacotherapy plan for melanoma.
- Develop a patient-specific pharmacotherapy plan for primary cutaneous t-cell lymphoma.
- Explain neuro-oncology risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
- Construct a patient-specific pharmacotherapy plan for neuro-oncology.
- Summarize gastrointestinal (GI) cancer risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
- Develop a patient-specific pharmacotherapy plan for gastrointestinal cancers.
- Develop a patient-specific pharmacotherapy plan for gastrointestinal stromal tumors.
Hematology and Stem Cell Transplant
ACPE: 0204-0000-25-888-H01-P
Application-based
4.5 contact hours
Learning Objectives:
- Given a patient case, choose an appropriate acute myeloid leukemia (AML) treatment regimen based on next-generation sequencing (NGS).
- Given a patient case, choose an appropriate acute lymphocytic leukemia (ALL) treatment regimen.
- Given a patient case, choose an appropriate chronic myeloid leukemia (CML) treatment regimen.
- Evaluate tyrosine kinase inhibitors (TKIs) based on patient characteristics and response.
- Given a patient case, choose an appropriate chronic lymphocytic leukemia (CLL) treatment regimen.
- Analyze patient risk factors in starting Bruton’s tyrosine kinase (BTK) inhibitors.
- Adjust multiple myeloma (MM) regimens based on patient lab values.
- Modify therapy in the management of a stem cell transplant recipient.
Hepatic and Renal Cancer
ACPE: 0204-0000-25-889-H01-P
Application-based
1.5 contact hours
Learning Objectives:
- Calculate a Child-Pugh Score.
- Choose a treatment regimen for a patient with hepatocellular carcinoma (HCC).
- Apply guideline recommendations when changing treatment of a patient with metastatic renal cell carcinoma (mRCC).
- Differentiate between immune-mediated vs. targeted therapy side effects.
Prostate Cancer
ACPE: 0204-0000-25-890-H01-P
Application-based
1.5 contact hours
Learning Objectives:
- Summarize prostate cancer risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
- Develop a patient-specific pharmacotherapy plan for localized prostate cancer.
- Develop a patient-specific pharmacotherapy plan for metastatic prostate cancer.
Thoracic Cancer
ACPE: 0204-0000-25-891-H01-P
Application-based
2 contact hours
Learning Objectives:
- Summarize non-small cell lung cancer (NSCLC) risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
- Develop a patient-specific NSCLC pharmacotherapy plan for an EGFR or KRAS-type mutation.
- Develop a patient-specific NSCLC pharmacotherapy plan for an ALK, ROS1, or BRAF-type mutation.
- Develop a patient-specific NSCLC pharmacotherapy plan for an MET, NTRK, or RET-type mutation.
Faculty Information
Jared Crumb, PharmD
Clinical Pharmacist
VCU Health
Richmond, Virginia
Sarah Kjenstad, PharmD, BCPS, BCOP
Clinical Pharmacist, Hematology/Oncology
Northwestern Medicine
Chicago, Illinois
Adjunct Assistant Professor
Midwestern University College of Pharmacy
Downers Grove, Illinois
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.
Methods and CE Requirements
Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Important Note – ACPE 60 Day Deadline:
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.
The ASHP Professional Certificates SM educational product line contains learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.
System Technical Requirements
ASHP learning content is delivered through your Web browser. For all learning content, you will need basic computer skills, the ability to navigate web pages and stable internet connection. View the system requirements for learning activities.